Retatrutide FDA approval: status, filing plan and timeline

Is retatrutide FDA approved? No. On Nov 12, 2026, retatrutide is not approved by the FDA or any other regulator [Lilly, Oct 28, 2026], and Lilly hasn't applied yet [7th Cir. filing, Oct 8, 2026]. So there's no retatrutide FDA approval date to report, and no release date either. Lilly says it plans to submit its application in the first three months of 2027 [Lilly, Sep 29, 2026].

This page lays out the dated timeline so far, what Lilly has said about filing, and how long FDA reviews usually take. It also covers the court case over what kind of product retatrutide is, and the two legal ways to get it while you wait. For the basics on the drug itself, start with what is retatrutide.

Is retatrutide FDA approved?

Not yet, and not anywhere. Lilly's own wording, from late October: Retatrutide is an investigational molecule that has not been approved by FDA or any regulatory organization anywhere in the world. [Lilly, Oct 28, 2026] Its retatrutide page says launch will depend on the completion of these trials and the regulatory approval process [Lilly, Oct 2026].

Approval needs an application first, and we found none in any country. Lilly's latest statements still describe the US filing as planned [7th Cir. filing, Oct 8, 2026]. The European Medicines Agency's November list of medicines under evaluation doesn't include retatrutide [EMA, Nov 10, 2026].

Where retatrutide stands in the approval process: the timeline

Retatrutide is in phase 3, the last stage of testing before a company files. Six phase 3 trials have reported results since December 2025, four of them now in peer-reviewed papers. A fifth paper covers sleep apnea results drawn from two of those trials [NEJM, Oct 21, 2026].

The numbers from each trial are in retatrutide weight loss results. More trials are still running. TRIUMPH-5 compares retatrutide with tirzepatide in about 800 adults. Its registry record estimates the main data collection ends in November 2026, and no results are posted [ClinicalTrials.gov, NCT06662383] [Lilly, Oct 28, 2026]. The heart and kidney outcomes trial runs much longer, with main results estimated for February 2029 [ClinicalTrials.gov, NCT06383390].

What has Lilly said about filing?

Lilly first named the quarter on Jul 23, 2026. Lilly said it is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA). The submission would follow in Q1 2027 [Lilly, Jul 23, 2026]. Before that, a filing had been expected later in 2026, BioSpace reported [BioSpace, Aug 5, 2026].

In early August, Lilly said its clinical data were complete to support registrations for obesity, sleep apnea and knee osteoarthritis pain [Lilly, Aug 5, 2026]. On Sep 29 it repeated the plan in one line: Lilly plans to submit a Biologics License Application (BLA) in Q1 2027 to the U.S. Food and Drug Administration. [Lilly, Sep 29, 2026]

Lilly's wording to a federal appeals court on Oct 8 was slightly looser. It said it plans to file no later than the first quarter of 2027 [7th Cir. filing, Oct 8, 2026]. Its third-quarter results release on Oct 29 gave no new filing date [Lilly, Oct 29, 2026].

Drug or biologic? The dispute behind the filing

Lilly calls its planned application a BLA, the form used for biologics. The FDA disagrees about what retatrutide is. On Mar 18, 2024, the agency classified it as a drug, not a biological product [7th Cir. brief, Apr 1, 2026]. The argument turns on size: under the FDA rule, a protein must be greater than 40 amino acids in size. Lilly says retatrutide has 41, while the FDA counts only 40 of them [7th Cir. brief, Apr 1, 2026].

Lilly sued. A federal court in Indiana ruled against Lilly on one issue in 2025 and sent the other back to the FDA [7th Cir. brief, Apr 1, 2026]. On Oct 2, 2026, the FDA again rejected Lilly's argument, according to Lilly's court filing [7th Cir. filing, Oct 8, 2026]. The appeal was argued in the Seventh Circuit on Sep 24, 2026, and the judges asked for extra briefs on whether they can hear it at all [7th Cir. order, Sep 24, 2026]. We found no ruling as of Nov 12, 2026.

Why it matters: Lilly told the court it needs to know which application pathway (biological product or drug) to pursue when filing [7th Cir. filing, Oct 8, 2026]. A drug normally goes through a New Drug Application (NDA). A BLA would bring 12 years of market exclusivity after approval, against 5 years for an NDA, AJMC reported [AJMC, Oct 7, 2026]. For the review clock, the label matters less. FDA's goals are the same for a new-molecule NDA and an original BLA [FDA, PDUFA VII goals].

How long does FDA review take?

FDA's timelines come from its commitments under the Prescription Drug User Fee Act (PDUFA). For a new molecule, FDA first takes 60 days after receiving the application to decide whether to file it, meaning accept it for review. Then the review clock starts [FDA, PDUFA VII goals].

• Standard review: FDA aims to act within 10 months of the 60-day filing date [FDA, PDUFA VII goals].
• Priority review: FDA aims to act within 6 months of that date [FDA, PDUFA VII goals]. Priority review goes to drugs that would be significant improvements in the safety or effectiveness of care for serious conditions. FDA tells the company within 60 days of receipt [FDA, priority review].
• Major amendment: a large new submission during review may extend the goal date by three months [FDA, PDUFA VII goals].

Two cautions. These are goals FDA commits to meet for 90% of applications, not promises for any one drug [FDA, PDUFA VII goals]. And "act" doesn't mean "approve." An action other than approval is a complete response letter, which means the application was not approved in that cycle [FDA, PDUFA VII goals].

What the review clocks imply (arithmetic, not a forecast)

What follows is simple arithmetic from Lilly's stated plan and FDA's published goals. It is not a prediction of when the FDA will decide, and it is not a release date. It assumes Lilly files in Q1 2027, the FDA accepts the filing, and the FDA meets its goal. Any of those can fail.

If FDA receives the application on any day from Jan 1 to Mar 31, 2027, add the 60-day filing period and then the review goal:

Clock rules from FDA [FDA, PDUFA VII goals]; filing quarter from Lilly [Lilly, Sep 29, 2026]. An approval also isn't the same as the drug reaching pharmacies, and Lilly hasn't said how fast it would launch.

What could speed it up or slow it down?

Faster. A national priority voucher is the biggest lever. FDA's voucher program targets review in 1-2 months, against 6 months or more for priority review [FDA, Oct 19, 2026]. In March 2026, FDA approved a higher dose of Wegovy 54 days after filing under a voucher. That was a new dose of an approved medicine, not a new molecule [FDA, Mar 19, 2026]. Lilly's pill orforglipron received a voucher in November 2025 [FDA, Nov 6, 2025]. No voucher for retatrutide has been announced, and FDA's voucher page doesn't name it [FDA, Oct 19, 2026]. Priority review is the other option, and nobody has said whether retatrutide will get it.

Slower. Manufacturing data come first: Lilly is still finishing its CMC package [Lilly, Jul 23, 2026]. In August, Lilly's CEO said the company was still collecting some manufacturing-related data, BioSpace reported. The same article said the drug could be delayed if FDA rejects a BLA [BioSpace, Aug 5, 2026]. A major amendment during review can add three months [FDA, PDUFA VII goals]. We found no statement on whether FDA will call an advisory committee meeting.

Is retatrutide available outside the US?

No. Australia's regulator, the TGA, said in September that retatrutide has not been approved by the TGA or any comparable international regulator [TGA, Sep 14, 2026]. Europe's medicines agency lists no retatrutide application under evaluation [EMA, Nov 10, 2026]. Lilly says its clinical data support global submissions, but it hasn't named a country or a date [Lilly, Jul 23, 2026].

Retatrutide clinical trials: which are recruiting?

On Nov 12, 2026, ClinicalTrials.gov listed 33 studies with retatrutide as an intervention. Of those, 21 were completed, 9 were active but no longer recruiting, 2 were recruiting and 1 was the expanded access program [ClinicalTrials.gov, Nov 12, 2026]. Most of the big phase 3 trials are full.

The recruiting Lilly trial is a phase 3 study in fatty liver disease (MASLD), not a weight-loss trial [ClinicalTrials.gov, NCT07165028]. It plans to enroll about 4,500 adults and follow them for up to about 224 weeks. People are assigned by chance to retatrutide, tirzepatide or a placebo, so joining doesn't guarantee retatrutide. Entry depends on liver tests: liver fat of at least 8% and set ranges on two liver-scarring measures. People with a BMI under 25 or an A1C above 10% are excluded. On Nov 12, it listed 137 recruiting US sites in 34 states [ClinicalTrials.gov, NCT07165028].

The other "recruiting" record is a phase 2 study at one site in China. Its sponsor isn't Lilly, and we couldn't verify any link to Lilly, so we don't list it as a route [ClinicalTrials.gov, Nov 12, 2026].

How to find a retatrutide trial near me

1. On ClinicalTrials.gov, type retatrutide in the "Intervention/treatment" field.
2. Filter the status to "Recruiting" and "Not yet recruiting."
3. Add your city or ZIP code. Each record lists its sites and a contact.
4. Or call Lilly's trial information center at 1-877-285-4559, or text YES to 317-854-5591, weekdays 8 a.m. to 8 p.m. Eastern [Lilly Trials, Nov 2026].

The site checks whether you qualify and explains the study before you sign anything. Lilly says that for most of its trials, the medicine and visits cost the volunteer nothing. You learn about any costs or payments during informed consent [Lilly Trials, Nov 2026]. The retatrutide cost guide covers money in more detail.

What is Lilly's expanded access program?

Expanded access, sometimes called compassionate use, lets a patient with a serious condition try an unapproved drug outside a trial. The doctor, an ethics board (IRB) and the company all need to agree [FDA, Oct 29, 2026].

Lilly's program is narrow. The registry lists these conditions [ClinicalTrials.gov, NCT07629401]:

• Age 18 or older.
• A BMI of 35 or more despite sticking with the highest available dose of a weight-management medicine.
• Two or more serious or life-threatening complications of obesity.
• No way into a retatrutide trial, because of eligibility or distance.
• All standard options, including bariatric surgery, discussed with the patient.

You can't apply yourself. The treating doctor contacts Lilly, and patients and caregivers should be directed to their treating physician [ClinicalTrials.gov, NCT07629401]. Lilly supplies the drug at no cost. The doctor acts as the sponsor, gets IRB approval and handles safety reporting [Lilly Medical, Aug 26, 2026]. Availability also depends on geography, product supply, and detailed individual eligibility assessment [ClinicalTrials.gov, NCT07629401].

When will retatrutide be available?

Nobody can give you a date, because none exists. Before an approval comes a filing, then FDA's 60-day filing review, then the review itself. The arithmetic above shows where FDA goal dates would fall if every assumption held. It's not a launch date.

Until then, retatrutide can't legally be sold for human use [Lilly, Oct 28, 2026]. The guide to retatrutide for sale explains what online listings are and why they aren't the trial drug.